BLNK Stock Price: Blink Charging Co falls as investors blink, take profits, buying opportunity?

  • NASDAQ: BLNK is on the back foot on Wednesday, following its surge on Tuesday. 
  • The electric services company has been surging in recent days alongside the broader EV sector.
  • A potential collaboration with Ideanomics could spark an upswing in prices.

NASDAQ: BLNK has been having its fair share of stock gains – jumping from the $2 handle to above $6 as the Electric Vehicle sector enjoyed growing demand. Blink Charging Co. does not produce cars nor trucks – but rather focuses on charging them. The company claims to be among the largest owners or operators of EV charging stations, a significant achievement for the company founded in 2009. 

The Miami-Beach-based firm can, therefore, serve not only Elon Musk's Tesla – but a wide range of competitors. 

One potential hookup or plug-in could be with Ideanomics. the Delaware-registered electric EV maker has also seen its stocks surge and fall – due to short-sellers skeptical of its financials. Other candidates include Nikola and Workhorse – who is also venturing into pickup trucks so popular in America.

Can Blink Charging continue higher?

BLNK charging stock

NASDAQ: BLNK is falling on Wednesday – heading over 10% with the blink of the eye. Are investors getting cold feet or blinking. However, bulls must remember that trading is never a one-way street, and profit-taking makes sense after the robust rally.

 

At the time of writing, Blink is trading around $4.72, down some 17% from Tuesday's close but substantially above prices seen only on Monday. Moreover, it traded below $2 in early June, hitting a 52-week low of $1.25. 

Below $5, will NASDAQ: BLNK attract those looking to "buy the dip"? The stock has been on the radar of investors who saw its rise and stayed out. Will they see this fall as a buying opportunity and pile in? 

Broader stock markets are on the rise on the first day of the third quarter, buoyed by hopes for a coronavirus vaccine developed by Pfizer and BioNtech.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.